Skip to search formSkip to main contentSkip to account menu

1-hexylcarbamoyl-5-fluorouracil

Known as: 1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo-, CARMOFUR, HCFU 
An antimetabolite (pyrimidine analogue) antineoplastic derivative of 5-fluorouracil. (NCI)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Background and aimsThe purpose of the present trial was to clarify the efficacy of postoperative adjuvant chemotherapy including… 
1996
1996
Colorectal cancer is one of the major malignant diseases and, recently, its incidence appears to be increasing. Surgical… 
Review
1987
Review
1987
SummaryThree cases of leucoencephalopathy induced by carmofur (1-hexylcarbamoyl-5-fluorouracil), an antineoplastic derivative of… 
1981
1981
1. 1-Hexylcarbamoyl-5-fluoro[6-14C]uracil (14C-HCFU) administered orally to rats, rabbits and dogs at a dose of 20 mg/kg was well… 
1980
1980
A phase I study of a new fluorinated pyrimidine, 1-hexylcarbamoyl-5-fluorouracil (HCFU), was performed by a multi-institutional… 
1980
1980
1. The metabolic fate of a new antitumour agent, 1-hexylcarbamoyl-5-fluoro[6-14C]uracil (14C-HCFU) was compared with that of 5… 
1978
1978
1. The metabolic fate of a new antitumour agent, 1-hexylcarbamoyl-5-fluoro [6-14C]uracil (14C-HCFU) in rats after oral… 
1978
1978
Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) against Lewis lung carcinoma and B16 melanoma by long-term oral… 
1976
1976
Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil against various tumors was examined. Therapeutic ratio (ILSmax/ILS30) in L…